MannKind Corp. Stock Plummets to New 52-Week Low of $3.29

MannKind Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 3.29 on February 25, 2026. This marks a significant decline, as the stock has underperformed the broader market, with a one-year performance of -22.05% compared to the S&P 500's gain of 12.95%. The company's market capitalization stands at USD 1,701 million, and it currently has a price-to-earnings (P/E) ratio of 38.00. However, MannKind Corp. faces challenges reflected in its financial metrics, including a negative return on equity of -106.42% and a concerning debt-to-equity ratio of 3.09. The stock's price-to-book ratio is notably negative at -38.18, indicating a weak long-term fundamental strength. Despite a reported growth in operating profit at an annual rate of 36.97% over the last five years, the company's ability to service its debt remains weak, as evidenced by an average EBIT to interest ratio of -1.07. The stock's performance has been risky compared to its historical valuations, further contributing to its current market position.